Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (735)	11/16/1998 8:55:00 AM
From: Dauntless	Read Replies (1) \| Respond to of 834

Cacaito - which compound? <<Merck has already a very similar compound approved and I think on the market in the USA, or very close to market. TXB has a very tough race ahead.>> Which TXB compound are you referring to? Merck has nothing on the market that competes with Novastan. They have an anti-platelet drug that is used for unstable angina but not for HIT. They are rumored to have a compound for CHF in early development but it is has a different selectivity & not felt to be a competitor. Can you provide some of your details?